ScreenerHero

OABI OmniAb, Inc.

NAS · US · Healthcare · Biotechnology · omniab.com
4.560USD+4.83%Mkt Cap: 662.98M $P/E: —

OmniAb, Inc., a biotechnology company, licenses discovery research technology to pharmaceutical and biotech companies, and academic institutions to enable the discovery of therapeutics in the United States, Europe, Japan…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap662.98M USD
Enterprise Value599.37M USD
Revenue (TTM)38.46M USD
Gross Profit18.36M USD
Net Income (TTM)-64.78M USD
Revenue/Share0.31 USD
Last Price4.560 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees89
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-14.75
PEG—
EV/EBITDA-27.75
EV/Revenue15.59
P/S16.45
P/B2.43
EPS (TTM)-0.36
EPS (Forward)-0.29
52W Range
1.30079% of range5.430
52W High5.430 USD
52W Low1.300 USD
Profitability
Gross Margin98.38%
Oper. Margin-49.47%
EBITDA Margin-56.16%
Profit Margin-347.04%
ROE-24.26%
ROA-21.53%
Growth
Revenue Growth244.20%
Earnings Growth—
Cash Flow & Leverage
Operating CF-36.45M USD
CapEx (TTM)565.00K USD
FCF Margin-0.74%
FCF Yield-0.04%
Net Debt-33.08M USD
Net Debt/EBITDA1.53
Balance Sheet
Debt/Equity0.08
Current Ratio4.80
Quick Ratio4.53
Book Value/Sh1.79 USD
Cash/Share0.36 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating—
Target (Mean)8.400 USD
Upside (mean)+84.2%
Target Range5.000 USD – 11.00 USD
5.000+84.2% to mean11.00
# Analysts5
Ownership
Shares Out.145.39M
Float118.24M
Insiders15.28%
Institutions52.80%
Short Interest
Short Ratio2.7d
Short % Float5.38%
Short % Out.4.90%
Shares Short7.13M
Short (prev mo.)6.25M
Technical
SMA 503.925 (+16.2%)
SMA 2002.431 (+87.5%)
Beta1.37
S&P 52W Chg16.45%
Avg Vol (30d)2.17M
Avg Vol (10d)1.31M
Technical Indicators
RSI (14)53.3
MACD0.2451
MACD Signal0.3259
MACD Hist.-0.0807
BB Upper5.216 USD
BB Middle4.570 USD
BB Lower3.923 USD
BB Width28.30%
ATR (14)0.3440 USD
Vol Ratio (20d)1.08x